Hypertension: Prazopress is indicated in the treatment of all grades of essential (primary) hypertension and of all grades of secondary hypertension of variec etiology. It can be used as the initial and sole agent or it may be employed in a treatment program in combination with a diuretic and/or other antihypertensive drugs as needed for proper patient response. Renal blood flow and glomerular filtration rate are not impaired by long-term oral administration and thus Prazopress can be used with safety in hypertensive patients with impaired renal function.
Left Ventricular Failure: Prazopress is indicated in the treatment of left ventricular failure. Prazopress may be added to the therapeutic regimen in those patients who have not shown a satisfactory response or who have become refractory to conventional therapy with diuretics, with or without cardiac glycosides.
Raynaud's Phenomenon And Raynaud's Disease: Prazopress indicated in the treatment of Raynaud's phenomenon and Raynaud's disease.
Benign Prostatic Hyperplasia: Prazopress is indicated as an adjunct in the symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia. It is also of value in patients awaiting prostatic surgery.
Left Ventricular Failure: Prazopress is indicated in the treatment of left ventricular failure. Prazopress may be added to the therapeutic regimen in those patients who have not shown a satisfactory response or who have become refractory to conventional therapy with diuretics, with or without cardiac glycosides.
Raynaud's Phenomenon And Raynaud's Disease: Prazopress indicated in the treatment of Raynaud's phenomenon and Raynaud's disease.
Benign Prostatic Hyperplasia: Prazopress is indicated as an adjunct in the symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia. It is also of value in patients awaiting prostatic surgery.